Crispr Therapeutics shares tumble after significant earnings miss
Reed Arian Simone, a director at Steven Madden , Ltd. (NASDAQ:SHOO), recently sold shares of the company’s common stock. According to a recent SEC filing, Simone sold 25 shares at a price of $23.20 each, totaling $580. The stock has shown strong momentum recently, posting a 14% gain in the past week, though it remains significantly below its 52-week high of $50.01. Following this transaction, Simone’s direct ownership stands at 10,157 shares. The company, currently trading at 9.9x earnings and maintaining dividends for 8 consecutive years, appears undervalued according to InvestingPro analysis, which offers 10+ additional investment insights for this stock.
In other recent news, Steven Madden Limited reported its first-quarter earnings for 2025, surpassing expectations with an earnings per share (EPS) of $0.60, compared to the forecasted $0.46. However, the company’s consolidated revenue slightly missed the mark, coming in at $553.5 million versus the anticipated $556.3 million. The company has withdrawn its 2025 financial guidance due to uncertainties related to new U.S. tariffs. In a strategic move, Steven Madden announced plans to significantly reduce its U.S. imports from China, aiming to decrease the proportion of China-sourced inventory to mid-single digits by spring 2026. Analyst Sam Poser from Williams Trading upgraded Steven Madden’s stock rating from Sell to Hold, citing the suspension of additional tariffs on Chinese goods as a positive development. Meanwhile, Citi analyst Paul Lejuez raised the stock’s price target to $26, acknowledging the company’s stronger-than-expected margins but maintaining a Neutral rating due to anticipated challenges such as potential order cancellations and lower margins. The company’s recent acquisition of Kurt Geiger is expected to support its international expansion efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.